MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of “Hold” from Analysts

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have earned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $7.00.

A number of analysts have recently weighed in on MXCT shares. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Prudential Financial Inc. bought a new position in MaxCyte in the 2nd quarter valued at $26,000. CWM LLC lifted its stake in shares of MaxCyte by 92.7% during the second quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after acquiring an additional 5,836 shares during the period. State of Wyoming acquired a new position in shares of MaxCyte during the second quarter valued at $38,000. Dynamic Technology Lab Private Ltd bought a new position in MaxCyte in the second quarter valued at about $40,000. Finally, Kwmg LLC increased its position in MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after purchasing an additional 11,135 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Price Performance

MXCT stock opened at $0.81 on Monday. The business has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.40. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.58. The stock has a market capitalization of $86.54 million, a price-to-earnings ratio of -1.84 and a beta of 1.22.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.